GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

Phase 2

Completed

• Conditions: Diabetes Mellitus, Type 2; Non-Insulin-Dependent Diabetes Mellitus

• Registration Number: NCT00291356
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2006-01
• Study First Submitted: 2006-02-13
• Study First Submitted QC: 2006-02-13
• Study First Posted: 2006-02-14
• Primary Completion: 2006-05
• Study Completion: 2006-05
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-14
• Last Update Posted: 2015-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety and tolerability: side effects and relevant changes in blood pressure, heart rate and ECG measurements, blood and urine measurements, the amount of fluid taken in and excreted, and kidney function will be monitored over course of study.

Secondary Outcome Measures

Name	Time	Method
Amount and percentage of glucose excreted in urine by kidneys. Effect of compounds on lipid metabolism analysed.

Trial Locations

Locations (1)

GSK Investigational Site; 🇩🇪 Berlin, Germany